Intervacc AB
2E9
Company Profile
Business description
Intervacc AB is a biotechnology company. It develops new vaccines based on recombinant proteins to meet the increasing need for effective vaccines in animal health care. The company through its subsidiary focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses on the Swedish market.
Contact
Vastertorpsvagen 135
Hagersten
StockholmS-129 44
SWET: +46 812010600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
16
Stocks News & Analysis
stocks
Are ASX REITs the better way to own property?
Cheap valuations, strong yields and a changing Aussie property landscape.
stocks
Cheap Dividend Aristocrat has Fair Value raised after earnings
Dividend forecasts raised after balance sheet regains strength.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,279.00 | 3.00 | -0.03% |
| CAC 40 | 8,597.04 | 39.75 | -0.46% |
| DAX 40 | 26,395.71 | 44.60 | -0.17% |
| Dow JONES (US) | 53,732.41 | 107.58 | -0.20% |
| FTSE 100 | 10,739.03 | 11.08 | -0.10% |
| HKSE | 25,453.23 | 336.38 | 1.34% |
| NASDAQ | 26,729.16 | 73.86 | -0.28% |
| Nikkei 225 | 69,220.25 | 506.45 | 0.74% |
| NZX 50 Index | 13,721.98 | 132.40 | -0.96% |
| S&P 500 | 7,785.76 | 0.00 | 0.00% |
| S&P/ASX 200 | 9,073.20 | 6.10 | -0.07% |
| SSE Composite Index | 3,982.65 | 55.48 | 1.41% |